ILC Therapeutics, has successfully closed a £3.5 million (US$4.9 million) pre-initial public offering (IPO) funding round.
UK-based biotechnology company, ILC Therapeutics, has successfully closed a £3.5 million (US$4.9 million) pre-initial public offering (IPO) funding round, it was announced in a Sept. 6, 2021 press release.
The funds raised will be used to accelerate the development of the company’s lead hybrid interferon, Alfacyte, which has been designed to combat viral infections, including COVID. Additionally, the company has strengthened its board with three new appointments.
“We are very pleased to complete this important funding round and to strengthen the [b]oard with the appointment of Robert Kopple, Professor David Harrison, and Chris Brinsmead,” said Peter Bains, chairman of ILC Therapeutics, in the press release. “With this funding in place, ILC Therapeutics is now well positioned to strengthen its novel technology platform and to advance its lead candidate, Alfacyte, through [investigational new drug] enabling studies in preparation for clinical trials as an anti-viral therapeutic for COVID-19.’’
“We are living through the most rapidly evolving viral environment the world has seen. Catalyzed by the global COVID crisis, governments and markets alike are recognizing the critical need for effective and safe antiviral medicines, both to meet the immediate challenges of today and the inevitable new threats of tomorrow. ILC Therapeutics Hybrid interferon platform technology is well positioned to address these needs, and Alfacyte, our lead candidate, has the potential to become an important antiviral treatment in the ongoing global fight against Covid-19, and future pandemic threats,” said Alan Walker, CEO, ILC Therapeutics, in the press release.
Source: ILC Therapeutics
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.